Latest News

The earlier baricitinib for severe alopecia areata is started, the better


 

AT AAD 2023

Baseline severity and treatment response

“Does treatment response vary with baseline disease status?” Dr. Chovatiya asked. “Yes. People with very severe hair loss [defined as a SALT score of 95 or higher] tended to do worse, while the rest of the study population did even better – an almost twofold difference. This means that you want to treat as early as you possibly can. It’s interesting to note that you don’t see this difference as much in the case of eyebrows and eyelashes. This makes sense, though. Eyebrows and eyelashes probably behave differently in terms of growth than the scalp does.”

Certain baseline characteristics of patients in BRAVE-AA1 and BRAVE-AA2 portended better outcomes. Women tended to fare better than men, but individuals who had longer histories of AA did not respond well. “People who had a shorter duration of their current episode of AA also did better than people who had a longer current episode, so we want to think about treating as soon as we possibly can,” Dr. Chovatiya said.

Dr. Chovatiya disclosed that he is a consultant to, a speaker for, investigator, and/or a member of the advisory board for several pharmaceutical companies, including Eli Lilly.

Pages

Recommended Reading

FDA OKs first systemic treatment for alopecia areata
MDedge Pediatrics
Hair disorder treatments are evolving
MDedge Pediatrics
Skin-picking, hair-pulling disorders: Diagnostic criteria, prevalence, and treatment
MDedge Pediatrics
Review cautions against influencer-promoted hair-growth remedies
MDedge Pediatrics
Uncombable hair syndrome: One gene, variants responsible for many cases
MDedge Pediatrics
Expert calls for thoughtful approach to curbing costs in dermatology
MDedge Pediatrics
Alopecia areata: Positive results reported for two investigational JAK inhibitors
MDedge Pediatrics
Study evaluates features of alopecia areata in Hispanic/Latinx patients
MDedge Pediatrics
A toddler presents with a dark line on a fingernail
MDedge Pediatrics
Topical or intralesional cidofovir an option for recalcitrant warts
MDedge Pediatrics